🌸 Vasomotor Symptom Hot Flash Treatment Simulator

The Narrowing Thermoneutral Zone

A tighter core temperature window triggers flashes at smaller deviations.

• ~0.4°C: Normal zone width (placeholder reference range)
• ~0.0°C: Menopausal zone width (placeholder narrowed range)
• Perimenopause: Onset timing (placeholder typical window)
• ~75%: Prevalence (placeholder women affected)

Preoptic hypothalamus and the sweating/shivering thresholds

Placeholder: narrowed zone brings sweating and shivering thresholds close together.

Estrogen Decline Triggers Vasomotor Instability

KNDy neuron hyperactivity drives sudden vasodilation and flushing.

• Neurokinin B: Key neuropeptide (placeholder KNDy signaling)
• Rapid: Estrogen drop (placeholder perimenopausal decline)
• 1–5 min: Flash duration (placeholder typical episode)
• Late peri.: Peak frequency (placeholder timing note)

KNDy neuron hyperactivation mechanism

Placeholder: KNDy neuron hypertrophy disrupts thermoregulatory signaling.

Hormone Therapy as First-Line Treatment

Estrogen replacement is the most effective vasomotor symptom treatment.

• ~75%: Efficacy (placeholder symptom reduction)
• Oral/patch/gel: Formulations (placeholder delivery routes)
• If uterus intact: Progestin need (placeholder safety note)
• Weeks: Onset of relief (placeholder response time)

Estrogen restores thermoneutral zone width

Placeholder: systemic estrogen widens the zone and stabilizes KNDy signaling.

Placeholder: individualized risk-benefit assessment guides hormone therapy use.

Non-Hormonal Pharmacologic Options

SSRIs, SNRIs, gabapentin, and NK3 antagonists offer alternatives.

• ~50–60%: SSRI/SNRI efficacy (placeholder reduction estimate)
• Night symptoms: Gabapentin use (placeholder indication)
• Fezolinetant: NK3 antagonist (placeholder novel class)
• Breast cancer hx.: Contraindication use (placeholder clinical note)

Non-hormonal mechanisms of action

Placeholder: these agents modulate serotonergic and neurokinin pathways.

Severity-Based Treatment Selection

Treatment intensity should scale with frequency and patient risk.

• Lifestyle first: Mild cases (placeholder approach)
• Hormone/non-hormonal: Moderate cases (placeholder approach)
• Combination therapy: Severe cases (placeholder approach)
• Periodic review: Follow-up (placeholder monitoring note)

Shared decision-making framework

Placeholder: match frequency, severity, and contraindications to therapy choice.

Placeholder: reassess treatment response and adjust periodically.